secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0000950142-22-002339
Event type: leadership
Sentiment:  negative
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals Chief Corporate Officer, General Counsel & Corporate Secretary resigns effective July 22, 2022
--------------------------------------------------------------------------------

- Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary, effective July 22, 2022.
- Resignation not due to any disagreement with management or board regarding operations, policies, or practices.
- Ms. Daigneault left to pursue other personal and professional interests.
- No successor named in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/0000950142-22-002339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/eh220274812_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-002339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer